SOUTH SAN FRANCISCO, Calif. – April 29, 2004 – AGY Therapeutics Inc., a privately-held biotechnology company, announced today that it has moved its corporate headquarters to 270 E. Grand Avenue, South San Francisco, CA 94080, effective today.

These new facilities will better meet our needs at a critical stage in the company’s evolution," said Cynthia J. Ladd, AGY Therapeutics’ president and chief executive officer. “Our proprietary functional genomics-based platform coupled with our central nervous system discovery and development capabilities have provided several promising preclinical drug candidates for the treatment of CNS disorders. Our lead product candidate to aid in the recovery of stroke is scheduled to enter the clinic in the fourth quarter of 2004 and we are proceeding with the completion of the necessary preclinical studies on several other promising drug candidates.”

The new South San Francisco headquarters provides a 25,000-square-foot, state-of-the-art facility that will accommodate all employees. Importantly, the new building will support all IND enabling pre-clinical activities, including medicinal chemistry research laboratories that were not available in the previous location, as well as provide for AGY’s growing clinical development capabilities.

About AGY Therapeutics
AGY Therapeutics, a privately-held biotechnology company, is dedicated to discovering and developing breakthrough central nervous system therapeutics, including treatments for stroke, cognitive diseases, schizophrenia and brain tumors. AGY Therapeutics was founded to apply the latest molecular and cellular research techniques to central nervous system diseases. With its proprietary imAGYneTM platform, the company has identified and characterized a vast number of promising drug targets and compounds to treat these diseases.

For additional information contact:
Kristin Nash
WeissCom Partners
About AGY l Research & Development l Investors & Partners l AGY News l Career Opportunities l Contact Us